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Case Reports 
Primary Fibrinolysis in Acute Monocytic Leukemia 
Ellis J. Van Slyck, MD,* Sundara B.K. Raman, MD,t and Nalini Janakiraman, MD* 
We present the case of a young man with acute monocytic leukemia (French-American-British 
classification:M5) and systemic hy perfibrinoly sis with severe bleeding. Although fibrinolysis is 
usually mild and secorulary to disseminated intravascular coagulation, its role as a primary and 
domiruint factor in rare cases of leukemia warrants that its presence be sought as a cause of abnormal 
bleeding. Decreased serum plasminogen and increased serum plasmin determined by synthetic 
substrate assay and a negative protamine paracoagulation test are crucial findings. Use of high-dose 
epsilon-aminocaproic acid was effective in treating this complication. A transient increase in 
fibrinolytic activity coincident with the early effect of antileukemic treatment suggested that 
plasminogen activator and/or fibrinolytic protease substances were released from leukemic cells. 
Fibrinolytic activity subsequently disappeared with reduction in the population of leukemic cells. 
(Henry Ford Hosp MedJ 1989;37:33-6) 
A lthough thrombocytopenia is the abnormality associated with clinical bleeding in the majority of patients with acute 
leukemia (1), other disorders of coagulation are the principal 
culprits in some cases (2-6). The frequency of disseminated in-
travascular coagulation (DIC) in acute promyelocytic leukemia 
(French-American-British [FAB] classification:M3) is so well 
known that most clinicians treat patients thus afflicted with pro-
phylactic heparin before initiating antileukemic chemotherapy 
(7-9). In a smaller number of cases of acute nonlymphocytic leu-
kemia of all FAB types, the presence of DIC with or without 
secondary fibrinolysis has been described (10-15). Instances of 
apparent primary fibrinolysis, though rare, have been reported 
(16-19), although never previously in acute monocytic leukemia 
(FAB:M5). We report such a case and note some important diag-
nostic and therapeutic considerations. 
Case Report 
A 30-year-old carpenter came to the Emergency Room of Henry Ford 
Hospital on June 2, 1980, with atypical substernal pain. He was admit-
ted with a possible myocardial infarction. Physical examination dis-
closed no abnormalities. The following day the substernal pain spon-
taneously disappeared, and subsequent studies failed to implicate any 
cardiac disease. However, WBC count was noted to be 13.2 x lO'/L 
(13,200/|xL) with 0.17 (17%) polys, 0.38 (38%) lymphocytes, 0.05 
(5%) monocytes, 0.05 (5%) metamyelocytes, 0.23 (23%) myelocytes, 
0.02 (2%) promyelocytes, and 0.10 (10%) blasts. The hemoglobin was 
144 g/L (14.4 g%), hematocrit 0.42 (42 vol%), and the platelet count 161 
X 10''/L(161,000/fji,L). 
A bone marrow examinafion showed overall cellularity of 90% with a 
myeloid-to-erythroid ratio of 10:1. It was infiltrated by sheets of blasts 
which were large with sizable spongy nuclei and multiple nucleoli (Fig 
1). The cytoplasm of the blasts was abundant, blue, and occasionally 
vacuolated. Granulocytes were noted to be hypogranular. Special stains 
showed a strongly positive reaction to nonspecific esterase in most of 
the blasts. The Sudan Black B, specific esterase, periodic acid-Schiff, 
and toluidine blue stains showed nongranulocytic and nonlymphocytic 
reaction pattems. A diagnosis of acute monocytic leukemia (FAB:M5) 
was made. The patient was treated with doxombicin 60 mg/M^, vin-
cristine 2 mg, cytosine arabinoside 200 mg/M- days 1-7, and pred-
nisone 100 mg days 1-5 (ADOAP). Bone marrow examination on the 
eighth day showed 15% cellularity with no blasts present. On July 3rd, 
he had recovered from this induction course; his marrow was 70% cell-
ular and in complete remission. The patient then received three courses 
of consolidation treatment with ADOAP followed by monthly mainte-
nance with vincristine, cytosine arabinoside, and prednisone. He re-
mained in remission through March 4, 1981 (eight months). 
On April 22, 1981, the patient retumed with gross hematuria of two 
days' duration. He had also recently noted bmises on the anterior thighs 
and had experienced epistaxis and bleeding gums. The physical exam-
ination confirmed abnormal bruising. The urine was grossly bloody. 
Laboratory studies showed a hemoglobin of 162 g/L (16.2 g%), WBC 
count of 24 X lO'/L (24,000/jiL) with 0.12 (12%) blasts. The platelet 
count was 192 X lOVL (192,000/|JLL). Bone marrow examination 
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Fig 1—Bone marrow aspirate smear showing sheets of large 
blasts with abundant cytoplasm and sizable spongy nucleii con-
taining several nucleoli (Leishman stain, XIOOO). 
showed marked hypercellularity with 0.892 (89.2%) large primitive 
stem cells. These cells again showed 94% positivity with nonspecific 
esterase stain and were diagnostic of acute monocytic leukemia 
(FAB:M5) in relapse (Fig 2). 
The results ofthe coagulation investigation were as follows: activated 
partial thromboplastin time (APTT), done by modification of the 
method of Proctor and Rapaport (20) using automated APTT reagent 
(activator micronized silica) from General Diagnostics, was signifi-
cantly prolonged. One stage prothrombin time (PT) done by the method 
of Quick (21) using Ortho Brain Thromboplastin was also prolonged. 
Fibrinogen measured on Lancer fibrinogen analyzer using the Lancer 
fibrinogen determination reagent kit was 0.4 g/L (40 mg%) (normal 1.8 
to 4.1 g/L). Fibrin split products were measured by agglutination of 
latex particles. Initial level was 80 jxg/mL (normal < 10 |J.g/mL) and 
later increased to 160 \xg/mL. Factor VIII assayed by modified one 
stage APTT using the method of Egeberg (22) was increased to over 
200% (normal 50% to 150%), and Factor V detennined by the method 
of Stefanini (23) was slightly below normal (47%), as was Factor VII 
(47%), measured by the method of Owren and Aas (24). Protamine sul-
fate paracoagulation test (25) was consistendy negative for fibrin mono-
mers suggesting that fibrinolysis was the dominant pathologic process. 
Plasminogen and plasmin were assayed by using a synthetic fluo-
rogenic substrate, D-valine-lysine-5-amidoisophthalic acid by the 
method of Pochron et al (26) using a fluorogenic assay (Protopath™, 
Dade Corporation, Miami, FL). The plasminogen level was consis-
tently decreased, reaching levels below 1 CTAU (Committee on Throm-
bolytic Agents units)/mL (normal 3.1 ± 0 . 7 CTAU/mL). Plasmin was 
demonstrated in the serum before epsilon-aminocaproic acid was 
given, but subsequent tests were negative. 
These data were interpreted as indicating the presence of primary 
fibrinolysis. On April 24th, epsilon-aminocaproic acid was begun ini-
tially at an oral dose of 5 g every four hours; this was subsequentiy 
changed to 1 g every hour intravenously After 48 hours no new areas of 
ecchymosis were seen, and by 72 hours the hematuria was greatly im-
proved. On this date (April 27th), antileukemic treatment with ADOAP 
was reinstituted, and the epsilon-aminocaproic acid was continued. An 
exacerbation in fibrinolysis occurred shortly after chemotherapy was 
started, but then strikingly improved and disappeared over the next 
seven days. Because of the continued presence of leukemic cells in the 
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Fig 2—All leukemic blasts in this field show strong nonspecific 
positivity (alphanaphthol butyrate esterase, XIOOO). 
marrow, cytosine arabinoside was administered for an additional three 
days. On May 9th, 13 days after reinduction chemotherapy, the patient 
had recurrent hematuria and gum bleeding, but this was now thought to 
be due to thrombocytopenia since the fibrinolytic parameters were nor-
mal. Control of bleeding occurred after the patient received 10 units of 
random donor platelets. Epsilon-aminocaproic acid was stopped on 
May Uth, and the patient was discharged two days later, having com-
pleted chemotherapy and now in a clinically stable state. 
However, at home the patient began vomiting with hematemesis. He 
arrived in the Emergency Room in shock on May 14th. He was in severe 
respiratory distress, having aspirated vomitus. His coagulation param-
eters now indicated the presence of DIC. Despite intensive supportive 
measures, the patient died five hours later The pertinent relationships 
between chemotherapy, fibrinolytic therapy, and laboratory values dur-
ing the clinical course of this patient are depicted in Fig 3. 
Discussion 
Fibrinolysis as a primary factor causing significant bleeding 
in leukemia is controversial. It is usually thought to be a second-
ary response to DIC, but, with the use of techniques for the 
measurement of plasminogen and plasmin, its occurrence as a 
primary phenomenon in leukemia has been observed (18,19). 
Fibrinolytic activity derived from the proteases, elastase and 
cathepsin G, and from plasminogen activators have been re-
covered from disrupted normal and leukemic granulocytes and 
monocytes (27-29). A case of acute myelomonocyfic leukemia 
(FAB:M4) with symptomatic fibrinolysis has been reported, in 
which a protease with fibrinolytic activity and a plasminogen ac-
tivator were demonstrated in the serum (18). Chan et al (19) de-
scribed two patients with promyelocytic leukemia, in whom low 
plasminogen and alpha-2-plasmin inhibitor levels were associ-
ated with severe bleeding and in whom transexamic acid, a po-
tent analog of epsilon-aminocaproic acid available in Europe 
(30), was therapeutically effective. Schwartz et al (16) claim a 
predictive value in finding less than 30% levels of serum al-
Primary Fibrinolysis in AML—Van Slyck et al 
pha-2-plasmin inhibitor in patients with promyelocytic leuke-
mia. Such patients showed evidence of increased fibrinolysis 
and responded to aminocaproic acid treatment, but they also re-
ceived heparin because of evidence of DIC. 
Our case represents the apparent rarity of pure monocytic leu-
kemia associated with severe fibrinolysis, manifested clinically 
by severe bleeding. Decreased fibrinogen and plasminogen with 
elevated fibrin split products, a persistently negative protamine 
sulfate paracoagulation test, and a normal platelet count prior to 
chemotherapy strongly suggest the presence of marked (proba-
bly primary) fibrinolysis. The favorable, although gradual, 
response to aminocaproic acid gives further support to this 
impression. There is also indirect evidence to implicate the 
leukemic cell as the source of fibrinolytic activity, since pro-
gressive hemostatic improvement paralleled the reduction in 
leukemic cell population induced by chemotherapy. Transient 
worsening of the bleeding diathesis at the onset of chemotherapy 
was likely due to the greater release of fibrinolytic activators by 
the initial disruption of leukemic cells. After resolution of the 
hemostatic defect, as shown by the patient's clinical stability 
and the normalization of his coagulation parameters, the subse-
quent terminal bleeding episode was related to sepsis and shock 
which produced the not unexpected DIC. This was confirmed by 
a strongly positive protamine sulfate paracoagulation test and by 
other abnormalities indicating excessive consumption, ie, de-
creased Factors V and VIII. At autopsy tbe presence of small 
fresh fibrin thrombi in several pulmonary and a few renal capil-
laries gave further evidence of late-occurring DIC. 
Regarding treatment of the fibrinolytic episode, we found ep-
silon-aminocaproic acid to be effective, but prolonged and high 
dose (24 g/day intravenously) was necessary. Replacement of 
fibrinogen through transfusions of cryoprecipitate was addi-
tionally helpful. 
Because it is certainly an uncommon clinical problem in the 
course of acute leukemia, the presence of fibrinolysis could 
go unrecognized, overshadowed by the ubiquitous throm-
bocytopenia, or mistaken for DIC. We wish to draw attention to 
this possibility, since therapeutic options are critical; and we 
stress the value of the protamine sulfate paracoagulation test and 
the measurement of the serum plasminogen in the evaluation of 
the bleeding leukemic patient. 
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